Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 72, Issue 1, Pages 65-75Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2008.11.003
Keywords
Colorectal cancer; Hepatic metastases; Surgery; Neoadjuvant therapy; Survival; Disease-free survival
Categories
Ask authors/readers for more resources
Colorectal cancer (CRC) caused nearly 204,000 deaths in Europe in 2004. Despite recent advances in the treatment of advanced disease, which include the incorporation of two new cytotoxic agents irinotecan and oxaliplatin into first-line regimens, the concept of planned sequential therapy involving three active agents during the course of a patient's treatment and the integrated use of targeted monoclonal antibodies, the 5-year survival rates for patients with advanced CRC remain unacceptably low. For patients with colorectal liver metastases, liver resection offers the only potential for cure. This review, based on the outcomes of a meeting of European experts (surgeons and medical oncologists), considers the current treatment strategies available to patients with CRC liver metastases, the criteria for the selection of those patients most likely to benefit and suggests where future progress may occur. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available